Femasys Inc
NASDAQ:FEMY
Femasys Inc
Revenue
Femasys Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Femasys Inc
NASDAQ:FEMY
|
Revenue
$1.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Revenue
$20.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Revenue
$17.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Revenue
$22.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Revenue
$42.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Revenue
$8.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
Femasys Inc
Revenue Breakdown
Breakdown by Geography
Femasys Inc
|
Total Revenue:
1.6m
USD
|
|
United States:
1.1m
USD
|
|
International:
555.6k
USD
|
Breakdown by Segments
Femasys Inc
|
Total Revenue:
1.6m
USD
|
|
Operates As A Single Business Segment, Which ...:
1.6m
USD
|
Femasys Inc
Glance View
Femasys, Inc. operates as a medical device company that focuses on women's healthcare. The company is headquartered in Suwanee, Georgia. The company went IPO on 2021-06-18. The firm is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The firm also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.
See Also
What is Femasys Inc's Revenue?
Revenue
1.6m
USD
Based on the financial report for Dec 31, 2024, Femasys Inc's Revenue amounts to 1.6m USD.
What is Femasys Inc's Revenue growth rate?
Revenue CAGR 5Y
12%
Over the last year, the Revenue growth was 52%. The average annual Revenue growth rates for Femasys Inc have been 11% over the past three years , 12% over the past five years .
You don't have any saved screeners yet